Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1 16Phase NA 11Phase 1/2 7Phase EARLY_PHASE1 5Phase 3 4Phase 2/3 2Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Breast 3Gastrointestinal 2CNS 2Thoracic 1Other neoplasm 1Other hematologic neoplasm 1Other 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Overweight 1Obesity 1Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 10human papillomavirus vaccine, L1 type 16, 18 7olaparib 4niraparib 4Human Papillomavirus Recombinant Vaccine nonavalent 4Vaccines 3Saline Solution 3Papillomavirus Vaccines 3Medroxyprogesterone Acetate 3Carboplatin 3Bevacizumab 3pegylated granulocyte colony-stimulating factor 2liposomal doxorubicin 2fluciclovine F-18 2apatinib 2Sevoflurane 2Propofol 2Paclitaxel 2Aspirin 2semaglutide 1pegfilgrastim 1pazopanib 1palbociclib 1lenvatinib 1halofantrine 1ganirelix 1gadofosveset trisodium 1fosaprepitant 1follicle stimulating hormone, human, with HCG C-terminal peptide 1ferrous gluconate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Magnetic Resonance Spectroscopy × Gynecologic × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡